The Decipher (GenomeDX Biosciences) test differentiates men at higher risk for prostate cancer metastasis after prostatectomy from those at lower risk and adds prognostic value in comparison with widely used clinical and pathologic risk factors, a new meta-analysis shows.


http://www.medscape.com/viewarticle/881964#vp_2